Neurogene Inc.

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. The company's lead product candidate is NGN-401, a gene therapy packaged in an adeno-associated virus 9 (AAV9), currently in Phase 1/2 clinical trials for the treatment of Rett syndrome. Additionally, Neurogene is developing NGN-101, a conventional gene therapy candidate in Phase 1/2 trials for CLN5 Batten disease. The company leverages license agreements with institutions such as The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University to advance its pipeline.

Neurogene Inc. is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol NGNE. The company's stock trades in United States Dollars (USD). As a US-based biotechnology firm, its shares are primarily traded by investors in the United States and internationally through the Nasdaq exchange.

Neurogene Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing genetic medicines for rare neurological diseases. The company's work involves advanced gene therapy techniques, including the use of adeno-associated virus vectors, to address conditions like Rett syndrome and CLN5 Batten disease.

Neurogene Inc. is headquartered in New York, New York, United States. The company primarily serves the US market, as indicated by its country and region classification. Its clinical trials for NGN-401 and NGN-101 are likely conducted in the US, targeting patients with rare neurological diseases. The company's collaborations with US-based institutions further emphasize its focus on the American healthcare market.